GV Stock Overview
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genomic Vision Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.0018 |
| 52 Week High | €0.046 |
| 52 Week Low | €0.0014 |
| Beta | -0.67 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -91.30% |
| 3 Year Change | -99.77% |
| 5 Year Change | -99.32% |
| Change since IPO | -99.99% |
Recent News & Updates
Shareholder Returns
| GV | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | -1.8% |
| 1Y | -91.3% | -28.0% | -4.9% |
Return vs Industry: GV underperformed the French Biotechs industry which returned -15.8% over the past year.
Return vs Market: GV underperformed the French Market which returned 3.5% over the past year.
Price Volatility
| GV volatility | |
|---|---|
| GV Average Weekly Movement | 0% |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: GV has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 33 | Aaron Bensimon | www.genomicvision.com |
Genomic Vision Société Anonyme, a molecular diagnostics and technology company, engages in the development of single DNA detection tools for research and in vitro diagnostics in France. The company provides FiberPrep, a DNA extraction kit that delivers purified DNA solutions for molecular combing; FiberComb, a molecular combing system, which stretches single DNA molecules onto a vinyl silane glass surface; FiberVision S, an automated scanner that develops life science research applications of single DNA molecules analysis and delivers fluorescence imaging; FiberSmart, an analysis software for replication combing assays; and accessories, which include combicoverslips, disposable DNA reservoirs, coverslips stickers, and bench holders. It offers FiberProbes; HexaCard, a genomic vision molecular combing technology offering a streamline one-stop-shop solution for biomanufacturing industries; TeloSizer, a novel tool for measurements of physical telomere length that can be applied to various model organisms; and EasyComb, EasyScan, and EasyComb Plus services.
Genomic Vision Société Anonyme Fundamentals Summary
| GV fundamental statistics | |
|---|---|
| Market cap | €692.90k |
| Earnings (TTM) | -€10.62m |
| Revenue (TTM) | €1.56m |
0.4x
P/S Ratio-0.1x
P/E RatioIs GV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GV income statement (TTM) | |
|---|---|
| Revenue | €1.56m |
| Cost of Revenue | €134.00k |
| Gross Profit | €1.43m |
| Other Expenses | €12.05m |
| Earnings | -€10.62m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Feb 29, 2024
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 91.43% |
| Net Profit Margin | -679.16% |
| Debt/Equity Ratio | -16.5% |
How did GV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/09 07:30 |
| End of Day Share Price | 2024/02/09 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genomic Vision Société Anonyme is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hugo Solvet | Bryan Garnier & Co |
| Lionel Labourdette | Kepler Cheuvreux |
| Delphine Le Louet | Societe Generale Cross Asset Research |